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1. Introduction 
Among the problems posed by chronic diseases today, one of the most daunting is that 
posed by diabetes mellitus, which is a very significant public health problem resulting in 
substantial morbidity and mortality (American Diabetes Association, 2011). With the 
increasing life-expectancy of the world's population, increasing exposure to environmental 
trigger factors, the rising incidence of obesity, and lifestyle changes such as unhealthy diets 
and decreased physical activity, the prevalence of diabetes has risen dramatically over 
recent years and is now reaching epidemic proportions globally. This rapid increase is a 
significant cause for concern, with an additional 7 million diagnosed each year 
(International Diabetes Federation, 2011). Diabetes is now the fourth or fifth leading cause of 
death in most developed countries (International Diabetes Federation 2000). Globally, it is 
estimated that more than 200 million adults now have diabetes and this number is expected 
to increase alarmingly in the coming decades. By the year 2025, it is estimated that almost 
333 million people will have the disease (International Diabetes Federation 2006).  
Type 1 (insulin-dependent) diabetes accounts for 5% to 10% of all diagnosed cases. In 2003, 
approximately 4.9 million people (0.09% of the world’s population) were estimated to have 
type 1 disease, with Europe having the highest number of sufferers (1.27 million) followed 
by North America (1.04 million) and Southeast Asia (0.91 million). The highest prevalence of 
type 1 diabetes was in North America (0.25%) followed by Europe (0.19%) (International 
Diabetes Federation 2006). In 2002, there were an estimated 0.9 to 1.2 million people with 
type 1 diabetes in the USA (American Diabetes Association 2006). The incidence in recent 
years may have accelerated alarmingly as shown in a recent study from Finland where the 
rate increased from 31.4 per 100,000 per year in 1980 to 64.2 per 100,000 per year in 2005 
(Harjutsalo et al, 2008). 
In New Zealand, the incidence of type 1 diabetes has doubled in the last 15 years, reflecting 
international trends. In 2003, the estimated prevalence of type 1 disease among the 
population aged <25 years was 0.18%, with the total number of sufferers in this age range 
numbering 2540. The majority, 85% (2158 people), were of European descent, while 9% were 
Maori, 2.9% were Pacific peoples, and 3.0% were Asian (Wu et al. 2005). 
Although the life-expectancy of patients with type 1 (insulin-dependent) diabetes mellitus 
has vastly improved since the introduction of insulin, the ability of insulin injections to 
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reliably prevent wide fluctuations in blood glucose levels is often inadequate and many 
patients develop complications of the disease. These complications cause considerable 
disability and suffering, and their management has major morbidity and cost consequences. 
High blood glucose concentrations not only cause acute metabolic problems but also lasting 
and accumulative damage by chemical reaction (glycation, e.g. Haemoglobin A1c) with a 
host of physiologically critical proteins. Hence the long term damage to the cardiovascular 
system, eye, kidney, heart and nervous system. On the other hand, low blood glucose levels, 
known as hypoglycaemic episodes, are usually perceived by the patient and treated by 
ingesting glucose or food. But in a significant minority of patients, hypoglycaemic episodes 
are not perceived and may cause loss of consciousness. These can lead to fatal outcomes for 
the patient and sometimes for others, such as in situations where the patient is in control of 
a moving vehicle.  
For these reasons, the investment in, and search for, newer treatments that can provide a 
‘cure’ for the disease with normoglycaemic control, or that at least minimizes the damaging 
effects of extremely high and low blood glucose excursions with markedly better control of 
metabolic disturbances, has been energetically pursued. In terms of health economics, the 
benefits in preventing eye, heart and kidney diseases would more than justify a substantial 
investment in such research and development (Beckwith et al. 2010). 
1.1 Background and rationale for cell transplantation 
Insulin is essential for normal glucose metabolism. It is released by the beta-islet cells of the 
pancreas in response to rising blood glucose levels. The feedback mechanisms involved 
provide a precise, finely tuned response, keeping blood glucose at a concentration of around 
4.5mM. Type 1 diabetes is an endocrine disorder caused by autoimmune destruction of the 
beta-islet cells leading to insulin deficiency. Treatment by injecting various commercially 
produced insulins subcutaneously, while life-sustaining, can not provide the control of 
blood glucose provided by a full complement of functional islets. 
In order to optimize the control of blood sugar and thus prevent the acute and chronic 
damage, the most likely way to improve these outcomes is to replace the patient’s pancreatic 
islets with a new pancreas or new islets. Transplanting a whole new pancreas is a very 
demanding procedure that requires many resources and is found to be less than practical. 
1.1.1 Porcine islet cell transplants 
Among the newer treatment strategies that have been proposed, transplantation of 
pancreatic islets, obtained either from other human or animal donors, has received 
considerable attention worldwide. This is because islet transplantation can restore not only 
the insulin-secreting unit, but also the precise insulin release in response to rising blood 
glucose and multiple signals arising within and beyond the islets.  
Because human islet transplantation is limited by the shortage of human islet tissue, human 
embryonic stem cells or induced pluripotent stem (iPS) cells from the patient are being 
developed into transplantable insulin producing cells. Recent reports indicate that iPS cells 
may not be transplantable into mice of the same strain without immune rejection (Zhao et al, 
2011). The US FDA guidelines highlight concerns that stem cell derived lines may undergo 
malignant transformation or develop into teratomas after transplantation (Fink et al 2009). 
While stem cell line-derived insulin producing cells are still at an early stage of research, pig 
islets are viewed as a promising alternative since: (a) the supply of pig pancreatic cells can be 
www.intechopen.com
 Cell Replacement Therapy: The Rationale for Encapsulated Porcine Islet Transplantation 
 
393 
increased by breeding more donor animals; (b) pig and human insulins have close structural 
and biological similarities; and (c) physiological glucose levels in pigs are similar to those in 
humans (Elliott, 2011). The rationale for this treatment approach (termed ‘xenotransplantation’) 
is that the implanted pig islets have the potential to mimic the normal physiological insulin 
response in type 1 diabetics, such that near-normal blood glucose levels may be achievable 
without insulin injections or with reduced requirements. As a consequence, long-term diabetes 
complications may be prevented and patients should experience less hypoglycaemia than they 
do with the currently recommended ‘intensive’ insulin regimens. Thus the need and rationale 
for improved diabetes control is clear but the effectiveness and practicality of islet transplants, 
whether from human, porcine or other sources, has yet to be firmly established. As with any 
transplanted tissue, organ or cells, whether from human or animal, the host immune system 
must be considered. Immunosuppression has been studied and used extensively in islet 
transplant patients. An increasingly successful alternative is immune-isolation, that is to isolate 
the transplanted cells in capsules or devices that exclude immune cells and antibodies, but 
allow the free diffusion of glucose, insulin, nutrients and dissolved oxygen and carbon dioxide. 
The latter approach eliminates the risks associated with immunosuppression. 
Some of the key issues in implementing porcine islet xenotransplantation in the treatment 
of patients with Type 1 diabetes are: 
1.1.1.1 Have ‘proof of concept’ pre-clinical experiments demonstrated sufficiently effective 
improvement in the control of Type 1 diabetes in experimental animals? 
1.1.1.2 Have the risks to the patient’s safety been sufficiently evaluated, including: (a) the 
risk of transmission of infectious diseases; and (b) risks to the individual from the transplant 
procedure itself, including allergic reactions and other immunological responses that might 
compromise the success of the procedure. 
1.1.1.3 How rejection of the cells by the recipient’s immune system can be effectively 
prevented. 
1.1.1.4 Whether porcine islet xenotransplants can restore, at least partially, the normal 
regulation of blood glucose (as reflected in decreased insulin requirements and decrease in 
HbA1c), and the number of islets needed to achieve this. 
1.1.1.5 The duration of effectiveness of the transplanted islets (i.e. whether they remain 
effective over a sufficiently prolonged period to justify the inconvenience and cost of the 
procedure), and the extent to which the patient’s well-being is enhanced and long-term 
diabetes complications are prevented. 
1.1.1.6 Ethical considerations, including cultural, ethical and spiritual dimensions, informed 
consent issues, and measures to ensure animal welfare. 
1.1.1.7 If clinical trials are judged successful by rigorous independent review, will resources 
to expand the availability of the treatment be provided by commercial and/or government 
investment? 
2. Pre-clinical studies of porcine islet xenotransplantation in non-human 
primates and rodents 
The main body of information from our laboratory on the efficacy and safety of current 
preparations of porcine islets is derived from studies with islets sourced from Auckland 
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Islands Pigs. The Auckland Islands (AI) strain is unique due to its isolation for more than 
150 years on a sub-antarctic island and is free of pathogens commonly found in other pig 
herds. These animals are being bred in custom-constructed pathogen-free facilities for 
transplant purposes and are discussed in detail later in this chapter. 
2.1 Studies in non-human primates 
The first exploration of primate diabetes treatments with encapsulated porcine islets was 
undertaken by Sun Y et al (1996) in Toronto, Canada. This pioneering group prepared islets 
and enclosed them in alginate-polylysine capsules in the early 1980s (Sun AM et al, 1984; 
Sun Y et al, 1993). They were able to find a number of diabetic cynomolgus monkeys that 
were ideal for testing these encapsulated porcine islets. These animals responded very well 
to their encapsulated porcine islets transplant, with significant improvement of their 
diabetes for 120-800 days. This remarkable achievement was based on decades of research 
by AM Sun, Y Sun and their colleagues that began in the early 1970s. 
In a later non-human primate study the clinical efficacy and safety of an encapsulated neonatal 
porcine islet preparation was investigated in cynomolgus monkeys with streptozotocin (STZ)-
induced diabetes. The islet toxin streptozotocin is injected into the monkeys and causes insulin 
deficiency. Sixteen monkeys with the disease established were separated into two groups of 8: 
one group was given microcapsules containing living porcine islets and the other was given 
the same microcapsules but without islets in them. They received the microcapsule transplants 
in two doses three months apart by injection into the peritoneal cavity (Elliott et al, 2005). No 
immunosuppressive drugs were administered. 
In the group that received capsules containing islets, evidence of clinical activity was noted 
at 12 and 24 weeks after the first transplant; the reduction of the mean weekly insulin 
requirement relative to the control was 36% (p=.02) and 43% (p=.01), respectively at these 
time points. Blood glucose in the two groups were maintained to similar levels indicating 
that the reduced requirement for insulin injections in the treated group was significant. Both 
the islet-treated and control groups tolerated the transplant procedures well. No 
hypoglycaemic episodes or other adverse events were observed in the islet-treated group. 
There were no differences between the two groups of monkeys in body weight or 
hematology and liver enzyme parameters. Two deaths occurred, one in the islet-treated 
group from lobar pneumonia with disseminated lung abscesses at 13 weeks after the first 
transplant (despite systemic antibiotic therapy), and the other in the control (empty 
microcapsules) group as a result of a stroke that followed the development of 
hypoglycaemia due to failure to consume food after regular insulin therapy.  
At terminal autopsy of these monkeys (Figure 1), no gross inflammatory reactions to either 
encapsulated islets or the empty microcapsules were noted in the animals’ peritoneal 
cavities. The organs (liver, spleen, stomach, intestines, kidney, heart, lungs and brain) 
appeared normal . 
In another streptozotocin diabetic monkey study, where encapsulated adult porcine islets 
were used, and thus more similar to the adult human islet isolations, diabetes was 
successfully treated without immunosuppression (Dufrane et al, 2010). However, although 
efficacy was demonstrated with encapsulated islets, they lost their function after 2 weeks. 
Successful glucose control was achieved for 6 months using ‘monolayer cellular devices’ 
containing up to 30,000 Islet Equivalents (IEQ)/Kg of monkey weight, implanted in the 
abdominal subcutaneous tissue. 
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Fig. 1. Clusters of encapsulated porcine islets attached to the mesentery of a cynomolgus 
monkey. 
In contrast, Hering et al (2006) demonstrated that unencapsulated naked porcine islets, 
injected into the portal vein of the liver, could be used to reverse diabetes for 100 days in 
cynomolgus monkeys provided comprehensive immunosuppression was given. 
2.2 Studies in small animal models of diabetes 
The biocompatibility of encapsulated porcine islets and a dose-dependent effect on 
glycaemic control have been demonstrated in STZ-diabetic rats. Those that developed 
diabetes were separated into four groups that received intraperitoneal transplants of 
encapsulated neonatal porcine islets at increasing dosage. The doses, measured in IEQs, 
were 3000 IEQ (n = 7), 6000 IEQ (n = 6), 12,000 IEQ (n = 6) or 18,000 IEQ (n = 6) of the 
standard preparation or empty alginate microcapsules (n = 12), insulin requirements were 
significantly reduced in rats given the higher doses. Prior to transplantation, all rats had 
comparable blood glucose control with daily isophane insulin injections. At week 12 after 
transplantation, the reduction in the weekly average daily insulin dose was significantly 
greater in rats given doses of 18,000 IEQs (p < 0.01) or 12,000 IEQs (p < 0.05) compared 
with control animals that received empty alginate microcapsules. Insulin independence 
was attained in 3 of 6 rats given 18,000 IEQs, 3 of 6 given 12,000 IEQs, 2 of 6 given 6000 
IEQs. 1 of the 12 diabetic rats given empty alginate microcapsules did recover, a case of 
spontaneous islet regeneration which is a known confounding factor in small animal 
studies (Figure 2). 
Similar encouraging results were seen when streptozotocin-induced diabetic mice and 
genetically predisposed diabetic NOD mice were treated with encapsulated islets.  
Thus, immunosuppression may not be necessary when treating diabetes if the islets are 
efficiently sealed inside capsules or devices with semipermeable membranes. The capsule or 
device outer membranes exclude immune cells and immunoglobulins but must allow 
efficient diffusion of glucose, insulin, all nutrients and gases (oxygen, CO2)  necessary for 
cell nutrition. 
This information about the efficacy of encapsulated islets and their tolerance by animal 
recipients, including some earlier human clinical studies, were assembled in great detail for 
the submission of applications to the National Regulatory Clinical Trial Agencies of several 
countries including New Zealand, Russia and Argentina, where the applications were 
successful, albeit with stringent conditions attached.  
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Fig. 2.  Percentage reductions in weekly averages of daily insulin doses 12 weeks after 
transplantation. Each point represents individual rats. Reduction of the insulin dose is 
calculated as the percentage of the baseline average daily insulin dose in the week prior to 
transplantation. In the three higher doses eight animals were insulin-independent at 12 
weeks. The bars represent the average % reduction in insulin dose for the respective groups. 
3. Xenotransplantation: Minimizing risks to patient’s safety 
The introduction of porcine islet transplantation has been delayed by concerns relating to 
the possible transmission of pig diseases to humans via the transplanted cells and the risk of 
introducing micro-organisms during cell processing and encapsulation. There is also a 
potential risk of transmitting porcine disease to close contacts of the human recipient and to 
the wider community. The risks of infection from the donor animal can be minimized by 
controlling the breed, source of and health status of the donor animals, with ongoing 
screening and quarantining. The risk of introducing micro-organisms during cell processing 
can be minimized by ensuring strict aseptic technique when isolating and encapsulating the 
islets.  
3.1 Risk of infections (‘xenoses’) resulting from transfer of pig micro-organisms to 
human recipients  
The risk of bacterial, fungal and parasitic infections can be minimized by the use of 
Designated Pathogen-Free pig herds and by monitoring and treating sows for such 
infections before pancreatic islets are extracted from their progeny (Garkavenko et al. 
2008a). However, this approach will not eliminate porcine endogenous retrovirus sequences 
(PERVs), which are present in the germline of all pigs (including common New Zealand pig 
breeds) but cause no known infection in the species. The possible transmission of these 
retroviruses to humans, and their as yet unknown consequences in recipients, have given 
rise to some concerns over the safety of xenotransplantation, particularly in view of reports 
that PERVs from certain pig strains can infect human cells in vitro (Patience et al. 1997; 
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Martin et al. 1998a) and that immune-incompetent SCID (severe combined 
immunodeficiency) mice may develop either microchimerism or infection in vivo (van der 
Laan et al. 2000). The in vitro findings have, however, been shown to be strain-specific 
(Patience 2001; Clemenceau et al. 2001; Oldmixon et al. 2002) and cells from animals studied 
by LCT have not shown retrovirus infectivity. Moreover, no evidence of PERV transmission 
has been detected over 200 patients who have been exposed to pig cells or tissues and tested 
for evidence of PERV infection using sensitive detection methods (Wynyard et al. 2011; 
Garkavenko et al. 2008b; Denner 2003; Dinsmore et al. 2000; Heneine et al. 1998; Heneine et 
al. 2001; Irgang et al. 2003; Martin et al. 1998b; Paradis et al. 1999; Patience et al. 1998; Tacke 
et al. 2001). In 2 New Zealand diabetic patients who received encapsulated porcine islet 
xenotransplants, no evidence of PERV proviral DNA or RNA was detectable in white blood 
cells and plasma up to 6 years after the transplant, and neither patient was found to have 
suffered any ill health as a result of the procedure (Elliott et al. 2000; Garkavenko et al. 
2004a). Similarly, in 4 other patients who received unencapsulated islets in similar studies in 
NZ, no infection has been found in a follow-up time of up to 9 years (Garkavenko et al. 
2004a). More recently one patient shown to have some functional transplanted porcine islets 
after 9.5 years was shown to be free of PERV.  
3.2 Porcine endogenous retrovirus 
In several other studies, no evidence of PERV transmission was found among recipients of 
porcine clotting factor VIII (Hyate:C) in a study of 88 haemophiliacs, despite the fact that all 
manufactured batches of porcine factor VIII concentrate used by patients were subsequently 
tested and shown to contain PERV RNA (Heneine et al. 2001). Similarly, no evidence of 
PERV DNA was found in 2 renal dialysis patients whose circulation had been linked 
extracorporeally to pig kidneys (Patience et al. 1998). 
3.3 Auckland Islands pigs 
A further refinement of the source herd has been obtained by the use of pigs derived from a 
colony abandoned on the Auckland Islands about 150 years ago. These animals are free of 
all measured viruses except the retrovirus (PERV), and are being bred for xenotransplant 
purposes in a purpose-built facility. Although PERV cannot be removed from the porcine 
genome, there is strong evidence that it is not functional in the Auckland Island Pig strain 
and is not expressed under any of the recommended testing conditions. This strain is now 
termed a “Null Pig Strain” suitable as a source of tissues for xenotransplantation (Wynyard 
et al, 2011).  
3.4 Neonatal pigs 
Nevertheless, the selection of donor animals that do not transmit infectious PERV continues 
to be important and has to be linked with the selection of donor animals bred in isolation 
and screened to exclude infection with other exogenous microbes. The use of donor neonatal 
piglets rather than adult pigs also has the advantage of limiting the exposure time of donor 
newborn animals to acquired infections as they age. 
3.5 No genetic modification  
The selection of piglets without genetic modification as a source of tissue offers another 
advantage. In attempting to prevent immune rejection of porcine tissue, genetically-modified 
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pigs with the gene for the xeno-antigen alpha-gal eliminated have been developed. However, 
with the use of alpha-gal gene knock-out pig donor cells, PERV-exiting cells are not enveloped 
(coated) with the alpha-gal antigen and hence are not recognised as ‘foreign’ by the recipient’s 
blood complement system (Fujita et al. 2003). It is known that normal human serum contains 
natural anti-alpha-gal antibodies that inactivate retrovirus (Rother et al. 1995).  
3.6 Intact immune system 
The maintenance of an intact immune system is an important safety factor. 
Immunosuppressive drugs are commonly used to prevent immune rejection of transplanted 
organs and cells. However, the use of alginate-encapsulated islets is intended to allow the 
survival of transplanted islets and their continued secretion of insulin in the recipient, 
without the need for life-long immunosuppressive drugs. 
3.7 Surveillance 
Long-term surveillance of recipients of porcine islet xenotransplants and testing of the 
transplant material for the presence of PERVs, using highly specific and highly sensitive assays 
developed for this purpose will always be an integral part of strategies proposed for future 
clinical trials. This safeguard, which is a necessary precaution recommended for clinical trials of 
xenotransplantation by authorities in various countries including the USA (US Department of 
Health & Human Services 2002, 2003), Australia (National Health & Medical Research Council 
2002), UK (United Kingdom Xenotransplantation Interim Regulatory Authority 1998, 1999), and 
Canada (Therapeutic Products Programme, Health Protection Branch, Health Canada 1999), is 
designed to allow early detection of infectious disease transmission, and includes standard 
hospital infection control measures to limit the spread of such an infection should one be 
detected. These carefully structured and independently monitored precautionary measures are 
now mandatory for all patients enrolled in clinical trials of porcine islet (or other cells) xeno-
transplantation and are put in place before the trials begin. 
4. Minimizing risks of contaminating with infective agents during product 
preparation 
After the pancreas is removed from the donor animal it must be treated with a series of 
procedures to isolate the insulin-producing islets, substantially free of the proteolytic 
exocrine tissue which makes up the majority of the pancreas. It is then kept in cell culture 
medium and tested for microbiological contamination and for its ability to produce insulin 
in response to stimulation by exposure to a glucose challenge. This must be done with every 
batch of islets produced for clinical use. The manufacturing facility, records and staff 
training need to be regularly inspected by expert teams from government health agencies.  
Samples of islets from every batch and biopsies of pancreas, heart, lung, spleen, kidney and 
brain tissues, also blood samples, from every donor animal must also be stored frozen at -80 
Centigrade as historical resources that can be retrospectively analyzed, in case of later 
complications in patients. 
5. Preventing rejection of islets by the recipient's immune system  
The vulnerability of transplanted islets to the recipient’s immune system has been a major 
scientific challenge and a barrier to successful islet transplantation. The transplanted cells 
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face not only Immediate Blood Mediated Immune Rejection (IBMIR) but also immune attack 
from a variety of cells which may result in loss of function and cell death. Two approaches 
are currently used to overcome this:  
5.1 Immunosuppressive drugs 
The administration of immunosuppressive drugs before a cell transplant and for the rest of 
the life of the patient. These procedures to manage the immune competence of the patient 
are essential in greater or lesser forms for all transplants of naked cells except perhaps those 
that are sourced from the patient (autotransplantation) or from a perfectly matched donor. 
Even then, any patient-derived cells (e.g. endogenous adult stem cells) that may be induced 
to mature into functional islet cells may be attacked by auto-immune processes engendered 
during the auto-immune destruction of the patient’s original pancreatic islets, since the 
newly matured islet cells carry essentially the same antigens (Zhao et al, 2011).  
A suppressed immune system, with lower surveillance of foreign antigens, can provide an 
opportunity for infection. Immunosuppressive agents may also prevent the essential 
immune surveillance that detects and destroys most cellular chance mutations that lead to 
cancer cell growth. This has been a serious concern about stem cell transplants that may 
contain a small number of viable undifferentiated cells that can exhibit uncontrolled 
replication and form tumours (Bauer SR, 2010). 
5.2 Immunoisolation 
Immunoprotection of the transplanted cells via the use of a semipermeable membrane that 
acts as a protective barrier (Figures 3a and 3b). The latter technique appears to be a viable 
approach, the principle being that the permeability of the outer capsule membrane allows 
smaller molecules such as glucose, dissolved oxygen and carbon dioxide and all nutrients to 
penetrate into the capsule and reach the islets. The membrane is constructed to allow insulin 
and most small proteins to be released out into the bloodstream, but it does not allow the 
passage of large immune cells or antibodies that would cause rejection of the islets. Indeed, 
the islets can survive well inside such systems. There are several approaches to providing 
this immunoprotection which are: 
 Encapsulation of the islets within a bead of alginate gel, which is then coated with poly-
L-ornithine, poly-L-lysine or some other material to provide perm-selectivity and 
strength (Calafiore 2006; Weir & Bonner-Weir 1997).  
 Tubular diffusion chambers which consist of long (up to 20mm) tubular membranes of 
5-6mm inner diameter. 
 Perfusion devices (also known as vascularised artificial pancreases) which consist of an 
outer housing 90 mm in diameter and 20 mm in width that is connected surgically to 
the patient’s vascular system so that it is fed by an artery and drained by a vein. Islets in 
both perfusion devices and diffusion chambers are usually immobilised with alginate or 
agar to prevent settling and to provide uniform distribution of nutrients and dissolved 
oxygen and carbob-dioxide (Maki et al. 1995). 
 Co-transplantation with ‘nursery’ cells such as testicular Sertoli cells which have been 
claimed to protect against immune-mediated rejection via the production of the 
immunomodulator TGF-beta1 (transforming growth factor-beta 1) (Suarez-Pinzon et al. 
2000; Valdes-Gonzalez, 2005). 
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Of these approaches, the strategy selected by Living Cell Technologies for intensive 
investigation is encapsulation of the islets in ‘minimal volume’ alginate microcapsules 
developed at the Department of Internal Medicine and Endocrine & Metabolic Services, 
University of Perugia in Italy (Calafiore 1997; Calafiore et al. 1999). Alginate-encapsulated 
porcine islets have been extensively investigated in experimental animals both with and 
without diabetes, and in a small number of human diabetic subjects.  
 
 
Fig. 3a. The concept of encapsulation: enclosure of the islet in an alginate/poly-L-ornithine 
or poly-L-lysine membrane that is permeable to glucose, nutrients and insulin, but not to 
lymphocytes and antibodies, provides protection against immune destruction of the cells. 
 
            
Fig. 3b. Islets isolated from neonatal porcine pancreas in alginate-polyornithine capsules. 
Green fluorescent stain (acridine orange) demonstrating viable cells and red tetra-methyl-
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6. Alginate-poly-l-ornithine capsules 
These capsules, as shown in Figure 3, have been the method of choice for many laboratories 
including our own (Opara & Kendall, 2002; Hernandez et al, 2010; Elliott, 2011).  Their 
biocompatibility is critical to their in vivo efficacy and durability. Alginate is derived from 
seaweed and has to be highly purified to remove contaminating heavy metals, proteins and 
endotoxins. Different sources of alginate vary in their chemical composition with different 
ratios of their main constituents of mannuronic acid and guluronic acids and hence their 
physical gel properties. The consistency of the microcapsules with respect to their size, wall 
thickness, compressibility and cell occupancy has to be ensured from batch to batch. The 
central core containing the islets is liquefied alginate and the outer surface is a membrane 
formed by ionic interaction between positively charged poly-L-ornithine (or poly-L-lysine) 
and negatively charged alginate. Properly made, the membrane is remarkably robust 
(Skinner et al, 2009). 
Since up to a million capsules may be required for treatment, the production must be 
reproducible, using durable equipment to Good Manufacturing Practice (GMP) standards. 
The main components are carefully engineered flow-through needles which generate 
reproducible sized droplets impelled by air ‘knife’ flows or electrostatic mechanisms 
(Hernandez et al, 2010). 
7. Ethical considerations 
Embodied in the wider concepts of informed consent are considerations that young people 
and the old or infirm are not exploited. Peoples with poor understanding of the language 
and scientific concepts involved are not to be misled. Religious and cultural feelings are not 
to be disregarded in potential recipients who find it difficult to express their reluctance to 
participate in the presence of those whom they perceive as medical authorities. 
The ethical issues of  xenotransplantation include concerns over the cultural, ethical and 
spiritual dimensions of xenotransplantation; the ethical acceptability of using animals to 
provide tissue for human transplantation; how the welfare of donor animals can be 
adequately protected and their suffering reduced; and how the welfare and interests of 
patients in early clinical xenotransplantation trials can be protected. These issues have been 
addressed by the Nuffield Council on Bioethics in the United Kingdom (1996) and, in New 
Zealand, the Bioethics Council, Toi te Taiao (2005). The latter body concluded that 
prohibition of xenotransplantation could not be justified, given the compelling human need 
argument, and that it should be allowed to develop in New Zealand, with that development 
being demonstrably shaped by the resolution and management of safety issues by a 
competent authority; the relationship between the majority European culture and 
indigenous Maori people and the cultural, ethical and spiritual factors that matter to most 
New Zealanders. 
In recent years, a number of recommendations to protect the ethical integrity of future 
human research have been made by various regulatory authorities. Key issues in the 
conduct of clinical trials of xenotransplantation include the requirement to provide patients 
with an explanation of the likely success, its attendant risks, and the subsequent quality-of-
life that can be expected when obtaining their informed consent, and informing patients that 
their consent to the procedure includes consent to ongoing post-transplantation 
microbiological monitoring.  
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Other international spiritual organisations have given their opinions about 
xenotransplantation. The Vatican in Rome, Italy have considered xenotransplantation in 
some depth and suggest it is worthy of serious consideration (Vatican, 2011). Jewish 
organisations have given qualified support to xenotransplantation as a life enhancing 
procedure while Muslim opinion is unclear but has generally been negative because of the 
status of pigs in the religious context.  
8. Clinical experiences with xenotransplantation in treating type 1 diabetes 
Many of the considerations in the preceding part of this chapter have been opinion and 
experiment seeking to determine the safety and efficacy of xenotransplantation for Type 1 
diabetes in animal models. These animal models are perhaps more or less imperfect as true 
reflections of the human condition of Type 1 diabetes. It is therefore of critical relevance to 
review all data and experiences relating to the small number of human exposures to 
xenotransplanted porcine islets and other cells. 
Six patients were treated in 1995-6 with either encapsulated or unencapsulated neonatal 
porcine islets.  One of these, a 41-yr-old Caucasian male with type 1 diabetes for 18 years 
was given an intraperitoneal transplant of alginate-encapsulated porcine islets at the dose of 
15,000 islet equivalents (IEQs)/kg bodyweight (total dose 1,305,000 IEQs) via laparoscopy. 
By 12 weeks following the transplant, his insulin dose was significantly reduced by 30% (p = 
0.0001). The insulin dose returned to the pre-transplant level at week 49. Improvement in 
glycaemic control continued as reflected by total glycated haemoglobin of 7.8% at 14 months 
from a pre-transplant level of 9.3%. Urinary porcine C-peptide, derived from the porcine 
pro-insulin precursor, peaked at 4 months (9.5 ng/ml) and remained detectable for 11 
months (0.6 ng/ml). The patient was followed as part of a long-term microbiologic 
monitoring program which subsequently showed no evidence of porcine viral or retroviral 
infection.  
The patient opted for elective laparoscopy 9.5 yr after transplantation. Abundant nodules 
were seen throughout the peritoneum. Biopsies of the nodules showed they contained 
capsules still protecting living cell clusters. Immunohistology noted sparse insulin and 
moderate glucagon staining cells. The retrieved capsules produced a small amount of 
insulin when placed in high glucose concentrations in vitro. An oral glucose tolerance test 
induced a small rise in serum of immuno-reactive insulin, identified as porcine by reversed 
phase high pressure liquid chromatography (Elliott et al, 2007). 
With this demonstration it was clear that this form of xenotransplantation treatment has the 
potential for sustained benefit in human type 1 diabetics. 
Since then two further human studies have started using porcine islets in microcapsules and 
without immunosuppressive drugs. In 2007, a pilot study with 8 patients was approved by 
the Scientific and Ethics Committees of the Sklifosovsky Institute, Moscow where islets were 
obtained from biocertified designated pathogen free pigs and encapsulated under GMP 
conditions in New Zealand. Adult patients were aged 23-63 with type 1 diabetes as defined 
by the American Diabetes Association criteria. They were insulin dependent for 5 -15 years. 
Before the implants, patients had to have stimulated plasma c-peptide levels < 0.2 ng/ml to 
confirm insulin deficiency.  Their diabetes had to be inadequately controlled with HbA1c of 
> 7% pre-implant. Patients were administered 5,000 or 10,000 islet equivalents per kilogram 
body weight (IEQ/kg). There were no significant adverse events and no evidence of 
zoonosis. Patients were also given repeat implants with no untoward effects.  Preliminary 
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data shows a reduction in daily insulin dose and reduction in HbA1c compared with pre-
implant values following the first implant (Tables 1 and 2) in the majority of patients. Two 
patients became insulin independent for a period, the maximum being 32 weeks. At the 
repeat implant, 6 months after the first implant, intact microcapsules were retrieved and 
subsequently found to contain viable cells. Porcine insulin was also detected in the 
circulation following glucagon stimulation. 
 
Patient ID 
Dose 1st Tx 
(IEQ/kg) 
Insulin Dose % Dose Reduction 
Pre 1st Tx 
Post-1st Tx 
3-month 6-month 
1 5,000 113 32 34 
2 5,000 22 100 32 
3 5,000 60 -7 5 
4 5,000 30 13 13 
5 5,000 68 15 16 
6 10,000 41 ? 0 
7 10,000 37 73 100 
8 10,000 83 0 0 
Mean 57 32 25 
Table 1. Reduction in daily insulin dose after first implant (Tx) in 8-patient pilot study. 
Patient 2 was insulin-independent at 3 months but subsequently needed insulin support. 
Patient 7 became insulin-independent at 6 months. 
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In 2009, a Phase I/IIa study approved by the New Zealand government following 
international peer review and Ethics Committee Approval was commenced. It will include 
14 adult patients. Unlike the preceding clinical studies, these patients were required to have 
unstable type 1 diabetes accompanied with hypoglycemic episodes. The patients are to be 
administered a single intra-abdominal implant of 5,000, 10,000, 15,000 or 20,000 IEQ/kg. To 
date no significant adverse events have been attributable to the treatment. At this early stage 
of the open label study, episodes of hypoglycemic unawareness (Figure 4) and 
hypoglycemic convulsions have been eliminated in the first patient. This was associated 
with significant reduction in the severity of hypoglycemic scores. A full one year follow-up 
of all patients is expected to be completed at the end of 2011. A third trial will be conducted 
in Argentina in 2011/2. The clinical studies are thus still at the stage of dose finding to 
determine the optimum dose and dosing regimen.   
 
 
Weeks  (time of implant at week 0) 
Fig. 4. Example of Elimination of Episodes of Unaware Hypoglycemia (Patient #1, Phase 
I/IIa Auckland, New Zealand) 
9. Conclusion 
Xenotransplantation is not yet standard treatment. There is current research into the 
feasibility of using donor animal organs such a kidney and liver. However, unlike cells, 
organs are difficult to screen against potential infectious agents. If clinical trials with cell 
transplants for diabetes are successful, porcine islet transplants will lead the way for the use 
of other cells for the treatment of nervous system disorders and enzyme deficiencies 
(Skinner et al, 2009).   
Porcine islet xenotransplantation has the potential to be beneficial for those with absolute 
insulin deficiency.  There is now a consensus that the procedure is relatively safe from 
xenotic infections. The results of several non-human primate and rodent studies indicate 
significant efficacy may be achieved. The early results of human clinical trials also suggest 
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that this form of treatment for Type 1 diabetes, without immunosuppression, is worthwhile. 
There is the concern that the treatment may be too expensive to be a practical treatment for 
the large numbers of patients who are expected to benefit from porcine islet implants. 
However, a health economic analysis of quality adjusted life years suggests that this 
approach may be cost effective taking into account the current cost of treating the disease 
and complications of cardiovascular disease, blindness, limb amputation, end-stage kidney 
disease and neuropathy (Beckwith et al, 2010). 
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